Last reviewed · How we verify

NCT05462665

Evaluation of the Intravenous Tissue Plasminogen Activator Treatment Algorithm of Nursing Intern Students

Completed NA Last updated 18 July 2022
What this trial tests

NA trial testing theory training in Acute Stroke in 75 participants. Completed in 1 March 2022.

Timeline
1 May 2020
Primary endpoint
1 March 2022
1 March 2022

Quick facts

Lead sponsorDokuz Eylul University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment75
Start date1 May 2020
Primary completion1 March 2022
Estimated completion1 March 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Dokuz Eylul University

Who can join

Adults 18 to 30, any sex, with Acute Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intravenous (IV) tissue plasminogen activator (tPA) is one of the key elements of acute ischemic stroke. In this study, acute stroke patients maximum benefit from the treatment, intravenous tissue plasminogen activator (IV tPA) minimizing the errors related to the treatment of acute ischemic stroke patients of nursing students from clinical practice guides published on the treatment of It is aimed to be informed and to standardize nursing interventions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Stroke

Currently open trials in the same condition.

Other Dokuz Eylul University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05462665.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing